COMPANY

T3D Therapeutics, Inc.

HQ: Research Triangle Park, NC source · t3dtherapeutics.com ↗ · Southeast

Keywords: neurology Alzheimer's disease mild to moderate alzheimer's disease alzheimer’s disease huntington's disease Alzheimer Disease T3D-959

Location: Research Triangle Park, NC · source · Oct 15, 2026

Profile checked Oct 10, 2026

3Trials (company is sponsor)13NIH grants

Timeline

Oct 26, 2026 Trial start 2: A Phase 2b/3 Clinical Study Evaluating T3D-959 in Mild-to-Moderate Alzheimer's Disease Subjects source ↗
Jul 24, 2025 Grant Government grant — SBIR: $203,807 (annual award, as published), announced Jul 24, 2025. Agency: NIH/NIA. Source: government award database. source ↗
Mar 1, 2021 Trial start Phase 2: Clinical Study Evaluating Efficacy and Safety of T3D-959 in Mild-to-moderate AD Subjects source ↗
2015-07 Trial start Phase 1/Phase 2: Feasibility Study in Subjects With Mild to Moderate Alzheimer's Disease source ↗

Upcoming milestones

2031-04 (ESTIMATED) · 2 · A Phase 2b/3 Clinical Study Evaluating T3D-959 in Mild-to-Moderate Alzheimer's Disease Subjects · NCT06964230

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Last 2 years.

Jul 24, 2025 Government grant — SBIR: $203,807 (annual award, as published), announced Jul 24, 2025. Agency: NIH/NIA. Source: government award database. source ↗

Clinical trials (lead sponsor) 3

Record	Title	Phase	Status	Start	Primary completion
NCT06964230	A Phase 2b/3 Clinical Study Evaluating T3D-959 in Mild-to-Moderate Alzheimer's Disease Subjects	2	Not yet recruiting	Oct 26, 2026	2031-04 (estimated)
NCT04251182	Clinical Study Evaluating Efficacy and Safety of T3D-959 in Mild-to-moderate AD Subjects	Phase 2	Completed	Mar 1, 2021	Jan 20, 2023 (actual)
NCT02560753	Feasibility Study in Subjects With Mild to Moderate Alzheimer's Disease	Phase 1/Phase 2	Completed	2015-07	May 30, 2016 (actual)

NIH awards 13

Annual award amounts. Total $26.2M.

May 17, 2024 NIH award 5R44AG082580-02 FY2024: $1,009,699 awarded for that fiscal year; activity R44 (SBIR); PI DIDSBURY, JOHN; recipient as written: T3D THERAPEUTICS, INC., RESEARCH TRIANGLE PARK, NC. Clinical Development Enable source ↗
Sep 4, 2023 NIH award 5R44NS127671-02 FY2023: $529,782 awarded for that fiscal year; activity R44 (SBIR); PI DIDSBURY, JOHN; recipient as written: T3D THERAPEUTICS, INC., RESEARCH TRIANGLE PARK, NC. Phase 2 Enabling Studies of a source ↗
Aug 8, 2023 NIH award 1R44AG082580-01 FY2023: $1,249,334 awarded for that fiscal year; activity R44 (SBIR); PI DIDSBURY, JOHN; recipient as written: T3D THERAPEUTICS, INC., RESEARCH TRIANGLE PARK, NC. Clinical Development Enable source ↗
Sep 22, 2022 NIH award 1R44NS127671-01 FY2022: $1,088,768 awarded for that fiscal year; activity R44 (SBIR); PI DIDSBURY, JOHN; recipient as written: T3D THERAPEUTICS, INC., RESEARCH TRIANGLE PARK, NC. Phase 2 Enabling Studies of source ↗
Apr 6, 2022 NIH award 5R01AG061122-04 FY2022: $1,520,269 awarded for that fiscal year; activity R01 (OTHER_NIH); PI DIDSBURY, JOHN; recipient as written: T3D THERAPEUTICS, INC., RESEARCH TRIANGLE PARK, NC. Phase 2 Randomized, Do source ↗
Feb 4, 2022 NIH award 3R01AG061122-03S1 FY2022: $5,526,538 awarded for that fiscal year; activity R01 (OTHER_NIH); PI DIDSBURY, JOHN; recipient as written: T3D THERAPEUTICS, INC., RESEARCH TRIANGLE PARK, NC. Phase 2 Randomized, source ↗
Feb 20, 2021 NIH award 5R01AG061122-03 FY2021: $5,526,539 awarded for that fiscal year; activity R01 (OTHER_NIH); PI DIDSBURY, JOHN; recipient as written: T3D THERAPEUTICS, INC., RESEARCH TRIANGLE PARK, NC. Phase 2 Randomized, Do source ↗
Jul 27, 2020 NIH award 3R01AG061122-02S1 FY2020: $2,396,962 awarded for that fiscal year; activity R01 (OTHER_NIH); PI DIDSBURY, JOHN; recipient as written: T3D THERAPEUTICS, INC., RESEARCH TRIANGLE PARK, NC. Phase 2 Randomized, source ↗
Feb 26, 2020 NIH award 5R01AG061122-02 FY2020: $3,102,477 awarded for that fiscal year; activity R01 (OTHER_NIH); PI DIDSBURY, JOHN; recipient as written: T3D THERAPEUTICS, INC., RESEARCH TRIANGLE PARK, NC. Phase 2 Randomized, Do source ↗
Apr 19, 2019 NIH award 1R01AG061122-01 FY2019: $2,292,799 awarded for that fiscal year; activity R01 (OTHER_NIH); PI DIDSBURY, JOHN; recipient as written: T3D THERAPEUTICS, INC., RESEARCH TRIANGLE PARK, NC. Phase 2 Randomized, Do source ↗
Jun 16, 2016 NIH award 3R44AG049510-02S1 FY2016: $100,000 awarded for that fiscal year; activity R44 (SBIR); PI DIDSBURY, JOHN; recipient as written: T3D THERAPEUTICS, INC., RESEARCH TRIANGLE PARK, NC. Clinical Evaluation of T3D- source ↗
Feb 16, 2016 NIH award 5R44AG049510-02 FY2016: $686,939 awarded for that fiscal year; activity R44 (SBIR); PI DIDSBURY, JOHN; recipient as written: T3D THERAPEUTICS, INC., RESEARCH TRIANGLE PARK, NC. Clinical Evaluation of T3D-95 source ↗
Mar 13, 2015 NIH award 1R44AG049510-01 FY2015: $1,127,955 awarded for that fiscal year; activity R44 (SBIR); PI DIDSBURY, JOHN; recipient as written: T3D THERAPEUTICS, INC., RESEARCH TRIANGLE PARK, NC. Clinical Evaluation of T3D- source ↗